Dasatinib impairs long-term expansion of leukemic progenitors in a subset of acute myeloid leukemia cases

Annals of Hematology

Volumn 89, Issue 9, 2010, Pages 861-871

  Han, Lina ^a,b   Schuringa, Jan Jacob ^a   Mulder, André ^a   Vellenga, Edo ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Acute myeloid leukemia; Dasatinib; KIT mutation; SRC family kinases

Indexed keywords

BCR ABL PROTEIN; DASATINIB; INTERLEUKIN 3; MITOGEN ACTIVATED PROTEIN KINASE 1; PROTEIN TYROSINE KINASE; STAT5 PROTEIN; STEM CELL FACTOR; THROMBOPOIETIN;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CANCER INHIBITION; CD34 SELECTION; CELL CULTURE; CELL DIFFERENTIATION; CELL PROLIFERATION; COLONY FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; LEUKEMIA CELL; MUTATION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; STEM CELL EXPANSION; STROMA CELL;

ANTIGENS, CD34; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; FETAL BLOOD; HUMANS; INFANT, NEWBORN; K562 CELLS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; SIGNAL TRANSDUCTION; STEM CELLS; STROMAL CELLS; THIAZOLES; TIME FACTORS;

EID: 77955658248     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-010-0948-7     Document Type: Article

References (39)

1. D Bonnet JE Dick 1997 Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell Nat Med 3 730 737 10.1038/nm0797-730 1:CAS:528:DyaK2sXkt1GrtLY%3D 9212098 (Pubitemid 27298715)
2. T Lapidot C Sirard J Vormoor B Murdoch T Hoang J Caceres-Cortes M Minden B Paterson MA Caligiuri JE Dick 1994 A cell initiating human acute myeloid leukaemia after transplantation into SCID mice Nature 367 645 648 10.1038/367645a0 1:STN:280:DyaK2c7ltVKrsg%3D%3D 7509044 (Pubitemid 24067706)
3. LM Kelly DG Gilliland 2002 Genetics of myeloid leukemias Annu Rev Genomics Hum Genet 3 179 198 10.1146/annurev.genom.3.032802.115046 1:CAS:528:DC%2BD3sXktlCkug%3D%3D 12194988 (Pubitemid 35217435)
4. LJ Lombardo FY Lee P Chen D Norris JC Barrish K Behnia S Castaneda LA Cornelius J Das AM Doweyko C Fairchild JT Hunt I Inigo K Johnston A Kamath D Kan H Klei P Marathe S Pang R Peterson S Pitt GL Schieven RJ Schmidt J Tokarski ML Wen J Wityak RM Borzilleri 2004 Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6- (4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino) thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays J Med Chem 47 6658 6661 10.1021/jm049486a 1:CAS:528:DC%2BD2cXhtVKrsrnI 15615512 (Pubitemid 40053752)
5. NJ Donato JY Wu J Stapley G Gallick H Lin R Arlinghaus M Talpaz 2003 BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571 Blood 101 690 698 10.1182/blood.V101.2.690 1:CAS:528:DC%2BD3sXkvVajsw%3D%3D 12509383 (Pubitemid 36077594)
6. C Gambacorti-Passerini M Gasser S Ahmed S Assouline L Scapozza 2005 Abl inhibitor BMS354825 binding mode in Abelson kinase revealed by molecular docking studies Leukemia 19 1267 1269 10.1038/sj.leu.2403775 1:CAS:528: DC%2BD2MXmvVOjurc%3D 15858616 (Pubitemid 40946015)
7. RA Van Etten 2004 Mechanisms of transformation by the BCR-ABL oncogene: new perspectives in the post-imatinib era Leuk Res 28 Suppl 1 S21 S28 15036938
8. MM Schittenhelm S Shiraga A Schroeder AS Corbin D Griffith FY Lee C Bokemeyer MW Deininger BJ Druker MC Heinrich 2006 Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies Cancer Res 66 473 481 10.1158/0008-5472.CAN-05-2050 1:CAS:528:DC%2BD28XhsFWltw%3D%3D 16397263 (Pubitemid 43166056)
9. PA Bromann H Korkaya SA Courtneidge 2004 The interplay between Src family kinases and receptor tyrosine kinases Oncogene 23 7957 7968 10.1038/sj.onc.1208079 1:CAS:528:DC%2BD2cXosFyltbg%3D 15489913 (Pubitemid 39468854)
10. M Okamoto F Hayakawa Y Miyata K Watamoto N Emi A Abe H Kiyoi M Towatari T Naoe 2007 Lyn is an important component of the signal transduction pathway specific to FLT3/ITD and can be a therapeutic target in the treatment of AML with FLT3/ITD Leukemia 21 403 410 10.1038/sj.leu.2404547 1:CAS:528: DC%2BD2sXhvFWktr0%3D 17230226
11. SC Dos C Demur V Bardet N Prade-Houdellier B Payrastre C Recher 2008 A critical role for Lyn in acute myeloid leukemia Blood 111 2269 2279 10.1182/blood-2007-04-082099 (Pubitemid 351451434)
12. MC Bene M Bernier RO Casasnovas G Castoldi W Knapp F Lanza WD Ludwig E Matutes A Orfao C Sperling MB van't Veer 1998 The reliability and specificity of c-kit for the diagnosis of acute myeloid leukemias and undifferentiated leukemias. The European Group for the Immunological Classification of Leukemias (EGIL) Blood 92 596 599 1:CAS:528:DyaK1cXksFaqsrY%3D 9657760
13. AS Advani C Rodriguez T Jin RA Jawde W Saber R Baz M Kalaycio R Sobecks M Sekeres B Tripp E Hsi 2008 Increased C-kit intensity is a poor prognostic factor for progression-free and overall survival in patients with newly diagnosed AML Leuk Res 32 913 918 10.1016/j.leukres.2007.08.019 1:CAS:528:DC%2BD1cXjs1Sltrc%3D 17928050 (Pubitemid 351389542)
14. A Beghini P Peterlongo CB Ripamonti L Larizza R Cairoli E Morra C Mecucci 2000 C-kit mutations in core binding factor leukemias Blood 95 726 727 1:STN:280:DC%2BD3c7itlSmtA%3D%3D 10660321
15. EA Kolb R Gorlick PJ Houghton CL Morton RB Lock M Tajbakhsh CP Reynolds JM Maris ST Keir CA Billups MA Smith 2008 Initial testing of dasatinib by the pediatric preclinical testing program Pediatr Blood Cancer 50 1198 1206 10.1002/pbc.21368 17914733 (Pubitemid 351555544)
16. C Ustun CL Corless N Savage W Fiskus E Manaloor MC Heinrich G Lewis P Ramalingam I Kepten A Jillella K Bhalla 2009 Chemotherapy and dasatinib induce long-term hematologic and molecular remission in systemic mastocytosis with acute myeloid leukemia with KIT D816V Leuk Res 33 735 741 10.1016/j.leukres. 2008.09.027 1:CAS:528:DC%2BD1MXivVajsrk%3D 18986703
17. D van Gosliga H Schepers A Rizo D van der Kolk E Vellenga JJ Schuringa 2007 Establishing long-term cultures with self-renewing acute myeloid leukemia stem/progenitor cells Exp Hematol 35 1538 1549 10.1016/j.exphem.2007.07.001 17889721 (Pubitemid 47419138)
18. JJ Schuringa H Schepers 2009 Ex vivo assays to study self-renewal and long-term expansion of genetically modified primary human acute myeloid leukemia stem cells Methods Mol Biol 538 287 300 10.1007/978-1-59745-418-6-14 1:CAS:528:DC%2BD1MXlsFersrg%3D 19277587
19. W Lawley H Hird P Mallinder S McKenna B Hargadon A Murray P Bradding 2005 Detection of an activating c-kit mutation by real-time PCR in patients with anaphylaxis Mutat Res 572 1 13 1:CAS:528:DC%2BD2MXisFKitrY%3D 15790486
20. S Yokota H Kiyoi M Nakao T Iwai S Misawa T Okuda Y Sonoda T Abe K Kahsima Y Matsuo T Naoe 1997 Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines Leukemia 11 1605 1609 10.1038/sj.leu.2400812 1:CAS:528: DyaK2sXnsV2iu7k%3D 9324277
21. JJ Schuringa KY Chung G Morrone MA Moore 2004 Constitutive activation of STAT5A promotes human hematopoietic stem cell self-renewal and erythroid differentiation J Exp Med 200 623 635 10.1084/jem.20041024 1:CAS:528: DC%2BD2cXns1Sgtbg%3D 15353555 (Pubitemid 39258311)
22. S Nam A Williams A Vultur A List K Bhalla D Smith FY Lee R Jove 2007 Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells Mol Cancer Ther 6 1400 1405 10.1158/1535-7163.MCT-06-0446 1:CAS:528:DC%2BD2sXktFams7Y%3D 17431118 (Pubitemid 46712003)
23. W Fiskus M Pranpat M Balasis P Bali V Estrella S Kumaraswamy R Rao K Rocha B Herger F Lee V Richon K Bhalla 2006 Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells Clin Cancer Res 12 5869 5878 10.1158/1078-0432.CCR- 06-0980 1:CAS:528:DC%2BD28XhtVartbnM 17020995 (Pubitemid 44629620)
24. TK Nguyen M Rahmani H Harada P Dent S Grant 2007 MEK1/2 inhibitors sensitize Bcr/Abl+ human leukemia cells to the dual Abl/Src inhibitor BMS-354/825 Blood 109 4006 4015 10.1182/blood-2006-09-045039 1:CAS:528:DC%2BD2sXkvFCiurY%3D 17218385 (Pubitemid 46641754)
25. K Nunoda T Tauchi T Takaku S Okabe D Akahane G Sashida JH Ohyashiki K Ohyashiki 2007 Identification and functional signature of genes regulated by structurally different ABL kinase inhibitors Oncogene 26 4179 4188 10.1038/sj.onc.1210179 1:CAS:528:DC%2BD2sXms1SksLs%3D 17213809 (Pubitemid 46920165)
26. RH Alvarez HM Kantarjian JE Cortes 2006 The role of Src in solid and hematologic malignancies: development of new-generation Src inhibitors Cancer 107 1918 1929 10.1002/cncr.22215 1:CAS:528:DC%2BD28Xht1Cms7fL 16986126 (Pubitemid 44582963)
27. SG Rane EP Reddy 2002 JAKs, STATs and Src kinases in hematopoiesis Oncogene 21 3334 3358 10.1038/sj.onc.1205398 1:CAS:528:DC%2BD38XksVWrsb8%3D 12032773 (Pubitemid 34587707)
28. KT Doepfner D Boller A Arcaro 2007 Targeting receptor tyrosine kinase signaling in acute myeloid leukemia Crit Rev Oncol Hematol 63 215 230 10.1016/j.critrevonc.2007.05.005 17658267 (Pubitemid 47126864)
29. LA Thoren K Liuba D Bryder JM Nygren CT Jensen H Qian J Antonchuk SE Jacobsen 2008 Kit regulates maintenance of quiescent hematopoietic stem cells J Immunol 180 2045 2053 1:CAS:528:DC%2BD1cXhsVSht7o%3D 18250409
30. D Kent M Copley C Benz B Dykstra M Bowie C Eaves 2008 Regulation of hematopoietic stem cells by the steel factor/KIT signaling pathway Clin Cancer Res 14 1926 1930 10.1158/1078-0432.CCR-07-5134 1:CAS:528:DC%2BD1cXkt1aktbo%3D 18381929 (Pubitemid 351551100)
31. S Matozaki T Nakagawa R Kawaguchi R Aozaki M Tsutsumi T Murayama T Koizumi R Nishimura T Isobe K Chihara 1995 Establishment of a myeloid leukaemic cell line (SKNO-1) from a patient with t(8;21) who acquired monosomy 17 during disease progression Br J Haematol 89 805 811 1:STN:280:DyaK2M3ptVequg%3D%3D 7772516
32. H Becker D Pfeifer JD Afonso SD Nimer H Veelken M Schwabe M Lubbert 2008 Two cell lines of t(8;21) acute myeloid leukemia with activating KIT exon 17 mutation: models for the 'second hit' hypothesis Leukemia 22 1792 1794 10.1038/leu.2008.61 1:CAS:528:DC%2BD1cXhtVyqu73N 18385756
33. M Copland A Hamilton LJ Elrick JW Baird EK Allan N Jordanides M Barow JC Mountford TL Holyoake 2006 Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction Blood 107 4532 4539 10.1182/blood-2005-07-2947 1:CAS:528: DC%2BD28Xlt1CgtrY%3D 16469872 (Pubitemid 43801382)
34. A Beghini CB Ripamonti R Cairoli G Cazzaniga P Colapietro F Elice G Nadali G Grillo OA Haas A Biondi E Morra L Larizza 2004 KIT activating mutations: incidence in adult and pediatric acute myeloid leukemia, and identification of an internal tandem duplication Haematologica 89 920 925 1:CAS:528:DC%2BD2MXjsF2jsLo%3D 15339674
35. P Paschka G Marcucci AS Ruppert K Mrozek H Chen RA Kittles T Vukosavljevic D Perrotti JW Vardiman AJ Carroll JE Kolitz RA Larson CD Bloomfield 2006 Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study J Clin Oncol 24 3904 3911 10.1200/JCO.2006.06.9500 1:CAS:528:DC%2BD28Xps1SitrY%3D 16921041 (Pubitemid 46630738)
36. LJ Robinson J Xue SJ Corey 2005 Src family tyrosine kinases are activated by Flt3 and are involved in the proliferative effects of leukemia-associated Flt3 mutations Exp Hematol 33 469 479 10.1016/j.exphem.2005.01.004 1:CAS:528:DC%2BD2MXisVCqu70%3D 15781338 (Pubitemid 40387630)
37. CM Orschell J Borneo V Munugalavadla P Ma E Sims B Ramdas MC Yoder R Kapur 2008 Deficiency of Src family kinases compromises the repopulating ability of hematopoietic stem cells Exp Hematol 36 655 666 10.1016/j.exphem.2008.01.002 1:CAS:528:DC%2BD1cXlslSisLc%3D 18346837
38. S Gueller S Gery V Nowak L Liu H Serve HP Koeffler 2008 Adaptor protein Lnk associates with Tyr(568) in c-Kit Biochem J 415 241 245 10.1042/BJ20080102 1:CAS:528:DC%2BD1cXhtFKhsbbF 18588518
39. J Seita H Ema J Ooehara S Yamazaki Y Tadokoro A Yamasaki K Eto S Takaki K Takatsu H Nakauchi 2007 Lnk negatively regulates self-renewal of hematopoietic stem cells by modifying thrombopoietin-mediated signal transduction Proc Natl Acad Sci U S A 104 2349 2354 10.1073/pnas.0606238104 1:CAS:528: DC%2BD2sXisVWrt74%3D 17284614 (Pubitemid 46391400)